Search Clinical Trials
Completed
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD (External Link)
Participation in this protocol will last about 1 year. To participate in this study, the patient will need to have undergone a stem cell transplant. Before the treatment starts, investigators …
Baylor Role:
Lead Sponsor
Completed
Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells (External Link)
Previously, some of the cancer cells taken from the patients body were separated in the laboratory and a specially produced human virus (adenovirus) that carries the IL-2 gene was put …
Baylor Role:
Lead Sponsor
Completed
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma (External Link)
ALASCER (Part 1 of 2) We will generate autologous (or syngeneic) or allogeneic LMP2A-specific cytotoxic T-cells and adoptively transfer them to patients with relapsed EBV-positive Hodgkin's or non-Hodgkins Lymphoma or …
Baylor Role:
Lead Sponsor
Completed
Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells (External Link)
This is a phase I trial to assess the safety of a dose escalation of hCD40L-expressing autologous tumor cells with a fixed dose of recombinant hIL-2 gene transduced autologous leukemic …
Baylor Role:
Lead Sponsor
Completed
Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease (External Link)
Subjects will receive the chemotherapy through a plastic tube (catheter) placed into a vein under the collarbone. The antibody rituximab is given on the day of admission. The subject will …
Baylor Role:
Lead Sponsor
Completed
Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL (External Link)
After subjects have completed the pretreatment evaluations, they will receive an injection of Enbrel - the study drug -(given under the skin) twice weekly. If the subjects disease stabilizes or …
Baylor Role:
Lead Sponsor
Completed
Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs). (External Link)
Participation in this study will be for one year. Patients will receive this treatment either while in hospital or in the outpatient clinic. Each patient will be entered into one …
Baylor Role:
Lead Sponsor
Completed
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H (External Link)
This is a two arm study in which outcomes will be assessed independently in recipients of HLA matched sibling transplants and recipients of unrelated or mismatched family donor transplants, although …
Baylor Role:
Lead Sponsor
Completed
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts (External Link)
To participate in this study, the subject will need to have a central line (a thin plastic catheter or tube that is placed during surgery into one of the large …
Baylor Role:
Lead Sponsor
Completed
Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes (External Link)
PROTOCOL OUTLINE: Patients undergo clinical, cytogenetic, and molecular studies. These include radiographic, neurologic, developmental, and 24 hour sleep studies, ophthalmologic, otolaryngologic, speech and language, and audiologic exams, echocardiogram, and renal …
Baylor Role:
Collaborator